Uporedna analiza potrošnje analgetika u Republici Srbiji i nordijskim zemljama u periodu 2015.-2018. godine
Sažetak
Uvod: Analgetici su lekovi koji se koriste u farmakoterapiji bola i jedni su od najpropisivanijih lekova u svim zemljama. Savremena farmakoterapija bola podrazumeva upotrebu analgetskih stepenica.
Cilj: Cilj ovog rada bio je da se analizira potrošnja lekova koji se koriste u farmakoterapiji bola u Republici Srbiji (RS), u periodu od 2015. do 2018. godine, i da se dobijeni rezultati kompariraju sa potrošnjom navedenih lekova u Kraljevini Norveškoj (KN) i Republici Finskoj (RF) u istom vremenskom intervalu.
Materijal i metode: Podaci o potrošnji lekova preuzeti su sa sajta Agencije za lekove i medicinska sredstva Srbije, zvaničnog sajta Norveškog instituta za javno zdravlje i zvaničnog sajta Agencije za lekove Finske. Potrošnja lekova se prati primenom metodologije definisane dnevne doze (DDD).
Rezultati: Potrošnja paracetamola je bila 13 do čak 20 puta manja u RS u odnosu na KN i 10 do 15 puta manja u odnosu na RF. Prosečna potrošnja diklofenaka tokom 4 posmatrane godine bila je oko 30 u RS, oko 7 u KN i oko 4 DDD/1000 stanovnika/dan u RF.
Zaključak: U farmakoterapiji bola u RS u potrošnji nesteroidnih antiinflamatornih lekova dominira diklofenak, a u KN i RF ibuprofen i paracetamol od neopioidnih analgetika.
Reference
1.1. Aydede M. Does the IASP definition of pain need updating? Pain Rep 2019; 4(5): e777. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882577/
2. 2. Republička stručna komisija za izradu i implementaciju vodiča u kliničkoj praksi; Nacionalni vodič dobre kliničke prakse za dijagnostikovanje i lečenje hroničnog bola maligne etiologije. Ministarstvo zdravlja Republike Srbije: Beograd, 2013. https://www.zdravlje.gov.rs/view_file.php?file_id=556&cache=sr
3. 3. Danilov A, Danilov A, Barulin A, Kurushina O, Latysheva N. Interdisciplinary approach to chronic pain management. Postgrad Med 2020; 132(Suppl 3): 5-9. https://www.tandfonline.com/doi/abs/10.1080/00325481.2020.1757305?journalCode=ipgm20
4. 4. Stevanović P, Nešić D, Lađević N et al. Medicina bola. CIBID, Medicinski fakultet, Univerzitet u Beogradu, Beograd, 2020.
5. 5. Jóźwiak-Bebenista M, Nowak JZ. Paracetamol: mechanism of action, applications and safety concern. Acta Pol Pharm 2014; 71(1): 11-23. https://www.ptfarm.pl/pub/File/Acta_Poloniae/2014/1/011.pdf
6. 6. Bacchi S, Palumbo P, Sponta A, Coppolino MF. Clinical pharmacology of non-steroidal anti-inflammatory drugs: a review. Antiinflamm Antiallergy Agents Med Chem 2012; 11(1): 52-64. https://pubmed.ncbi.nlm.nih.gov/22934743/
7. 7. Garcia Rodriguez LA, Cea-Soriano L, Tacconelli S, Patrignani P. Coxibs: pharmacology, toxicity and efficacy in cancer clinical trials. Recent Results Cancer Res 2013; 191: 67-93. https://pubmed.ncbi.nlm.nih.gov/22893200/
8. 8. Oldham JM. Opioids. J Psychiatr Pract 2020; 26(1): 1-2. https://journals.lww.com/practicalpsychiatry/Fulltext/2020/01000/Opioids.1.aspx
9. 9. Portenoy RK. A Practical Approach to Using Adjuvant Analgesics in Older Adults. J Am Geriatr Soc 2020; 68(4): 691-698. https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/jgs.16340
10. Radonjić V. Promet i potrošnja lekova za humanu upotrebu u Republici Srbiji 2015. Beograd: Agencija za lekove i medicinska sredstva Srbije; 2016. https://www.alims.gov.rs/wp-content/uploads/2022/01/011-Promet-lekova-2015.pdf
11. Radonjić V. Promet i potrošnja lekova za humanu upotrebu u Republici Srbiji 2016. Beograd: Agencija za lekove i medicinska sredstva Srbije; 2017. https://www.alims.gov.rs/wp-content/uploads/2022/01/PPL2017.pdf
12. Radonjić V. Promet i potrošnja lekova za humanu upotrebu u Republici Srbiji 2017. Beograd: Agencija za lekove i medicinska sredstva Srbije; 2018. https://www.alims.gov.rs/wp-content/uploads/2022/01/PPL2017.pdf
13. Radonjić V. Promet i potrošnja lekova za humanu upotrebu u Republici Srbiji 2018. Beograd: Agencija za lekove i medicinska sredstva Srbije; 2019. https://www.alims.gov.rs/wp-content/uploads/2022/01/PPL_2019.pdf
14. Norwegian Institute for Public Health. Drug Consumption in Norway 2015-2018. Oslo: Norwegian Institute for Public Health; 2023. http://www.legemiddelforbruk.no/english/
15. Finnish Medicines Agency Fimea. Finnish Statistics on Medicines 2015-2018. Helsinki: Finnish Medicines Agency Fimea; 2023. http://raportit.nam.fi/raportit/kulutus/laakekulutus_e.pdf
16. WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs, 2022. Oslo, Norway 2021. https://www.whocc.no/atc_ddd_index_and_guidelines/atc_ddd_index/
17. Tomić Z, Sabo A, Horvat O, Milijašević B. Osnovi farmakoekonomije i farmakoepidemiologije. Medicinski fakultet Novi Sad: Novi Sad, 2020.
18. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician 2008; 11 (2 Suppl): S133-153. https://www.painphysicianjournal.com/current/pdf?article=OTg3&journal=42
19. Beakley BD, Kaye AM, Kaye AD. Tramadol, Pharmacology, Side Effects, and Serotonin Syndrome: A Review. Pain Physician 2015; 18(4): 395-400. https://www.painphysicianjournal.com/current/pdf?article=MjM3OA%3D%3D&journal=89
20. Gan TJ. Diclofenac: an update on its mechanism of action and safety profile. Curr Med Res Opin 2010; 26(7): 1715-1731. https://www.tandfonline.com/doi/abs/10.1185/03007995.2010.486301?journalCode=icmo20
21. Chinese Rheumatism Data Center; Chinese Systemic Lupus Erythematosus Treatment and Research Group. Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications. Zhonghua Nei Ke Za Zhi 2017; 56(1): 81-85. https://pubmed.ncbi.nlm.nih.gov/32146743/
22. Irvine J, Afrose A, Islam N. Formulation and delivery strategies of ibuprofen: challenges and opportunities. Drug Dev Ind Pharm 2018; 44(2): 173-183. https://www.tandfonline.com/doi/abs/10.1080/03639045.2017.1391838?journalCode=iddi20
23. Singla AK, Chawla M, Singh A. Nimesulide: some pharmaceutical and pharmacological aspects--an update. J Pharm Pharmacol 2000; 52(5): 467-486. https://academic.oup.com/jpp/article/52/5/467/6157532?login=false
24. Ha MW, Paek SM. Recent Advances in the Synthesis of Ibuprofen and Naproxen. Molecules 2021; 26(16): 4792. https://www.mdpi.com/1420-3049/26/16/4792
25. Gatti D, Adami S. Coxibs: a significant therapeutic opportunity. Acta Biomed 2010; 81(3): 217-224. https://pubmed.ncbi.nlm.nih.gov/22530460/